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these in terms of health care resource use and associated
costs, e.g., costs of hospitalisations, diagnostic and surgi-
cal procedures, outpatient care and drug consumption.
Panel and literature data was used for events not investi-
gated in the clinical trials. Cost inputs were derived from
Tampere University Hospital for year 1998. Days in re-
mission and relapse were translated into Quality Ad-
justed Life Years (QALYs) using CD specific health-state
utility data from the literature. RESULTS: The outcomes
of the clinical trials were reflected in the model as a
26.4% reduction in annual number of relapses for the av-
erage patient in the budesonide CIR treatment group.
Mean annual health care cost per patient was 17,740
FIM (2,000 USD) for the budesonide CIR patient and
16,608 FIM (1,877 USD) for the NMT patient. The dif-
ference between the groups amounted to a cost per
gained QALY of 68,610 FIM (7,753 USD), which is well
in line with what is considered a cost-effective treatment
strategy. CONCLUSION: Budesonide CIR means fewer
relapses per average patient and is a cost-effective treat-
ment strategy for the treatment of Crohn’s disease in Fin-
land.
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OBJECTIVES: Gastroesophageal reflux disease (GERD)
is a common condition associated with a variety of symp-
toms, particularly heartburn. The purpose of this study
was to assess patient-reported symptom distress in a ran-
domized trial of rabeprazole (RAB), a proton pump in-
hibitor. METHODS: Symptom distress was measured us-
ing the Distress subscale of the GERD Symptom Assessment
Scale (GSAS) that asks patients about the degree of
bother they experience for 15 symptoms. Patients com-
pleted the GSAS at baseline and week 4. We evaluated
the impact of treatment (RAB 10mg, RAB 20mg, or pla-
cebo) on mean change in GSAS Distress scores using an
ANCOVA model. We also conducted a relative variabil-
ity analysis using ANOVA models to determine which of
5 clinical indicators are most useful to explain changes in
GSAS Distress scores. Mean change was assessed as a
function of baseline daytime heartburn severity, baseline
nighttime heartburn severity, time to first 24 hours with-
out heartburn symptoms, complete daytime heartburn re-
lief, and complete nighttime heartburn relief. RESULTS:
The sample consisted of 169 patients (RAB10mg  55,
RAB 20mg  56, placebo  58). Overall, a significant
difference in mean change in GSAS Distress scores was
observed across treatment groups (p  0.0007). Both the
RAB 10mg and RAB 20mg groups reported significantly
greater improvements in GSAS Distress scores than the
placebo group (p  0.0036 and p  0.0004, respectively).
Of the 5 clinical indicators examined, time to first 24
hours without heartburn explained the greatest amount
of variability in GSAS Distress scores. Achieving com-
plete daytime and complete nighttime heartburn relief
also were significant factors. CONCLUSIONS: In clinical
studies, RAB provided fast and consistent (both daytime
and nighttime) heartburn relief. Given that speed of
heartburn relief as well as achieving complete heartburn
relief were significant factors explaining variability in pa-
tient-reported symptom distress, the positive impact of
RAB on the GSAS distress scale was consistent with its
clinical efficacy.
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OBJECTIVES: With recent recognition of the primary
role of Helicobacter pylori (HP) in peptic ulcer disease, it
has been proposed that patients with dyspepsia undergo
noninvasive testing for HP, instead of endoscopy, fol-
lowed by antibiotics if positive. We evaluated cost-effec-
tiveness of ‘Test&Treat’ strategy versus empirical treat-
ment for HP infection in dyspeptic patients presenting in
the primary care setting. METHODS: The study was a
one-year incremental cost (yr2000 US dollars) per qual-
ity-adjusted life year (QALY) model for dyspeptic pa-
tients age less than 45 years old in a primary care setting
from a societal perspective. With ‘Test&Treat’ algo-
rithm, patients were tested for HP infection using urea
breath test. If positive, eradication was prescribed. Alter-
natively, patients were given conventional treatment of
H2RA for four weeks. If not cured, HP would be eradi-
cated empirically. Both direct and indirect costs were in-
cluded. The model took into consideration preventing
gastric cancer from eradication. Sensitivity analyses were
performed on prevalence of HP infection, drug treatment
efficacy, laboratory test costs, drug treatment costs, and
drug treatment utility loss. RESULTS: At baseline, with
HP prevalence of 40% and HP antibiotic eradication effi-
cacy of 89%, results showed that ‘Test&Treat’ had an in-
cremental cost-effective ratio (ICER) of $31,723/QALY.
One-way sensitivity analysis showed that antibiotic treat-
ment efficacies lower than 45–46% would exceed the so-
cietal threshold ICER of $50,000. CONCLUSIONS: The
model showed that ‘Test&Treat’ was cost-effective for
uncomplicated dyspeptic patients in primary care. Al-
though NIH guidelines state that all ulcer patients with
HP infection require eradication regimen, universal endo-
scopic diagnosis of ulcer causation (HP/HP) would not
be cost-effective. However, treating all patients empirically
could increase antibiotic resistance. The ‘Test&Treat’
strategy has the benefits of slowing antibiotic resistance
while avoiding high endoscopy costs. The model was ro-
